Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 4Recruiting 3Unknown 1

Sponsor Class

OTHER 11OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

EOM613 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Weight Loss × Clear all
NCT01206335 2012-11-27

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

Ohr Pharmaceutical Inc.

Phase 2 Unknown
20 enrolled

Anorexia, Fatigue, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡